PHAR

Pharming Group N.V. is a Dutch biopharmaceutical company specializing in the development and commercialization of protein replacement therapies and precision medicines for rare diseases. Headquartered in Leiden, Netherlands, the company operates globally with a commercial presence in over 30 countries across North America, Europe, and Asia-Pacific. Pharming's flagship product is RUCONEST® (conestat alfa), a recombinant human C1 esterase inhibitor approved for treating acute hereditary angioedema (HAE) attacks in adult and pediatric patients. The therapy is produced using the company's proprietary transgenic protein production platform in the milk of genetically modified rabbits. Pharming also markets Joenja® (leniolisib), acquired through its 2022 purchase of Novartis's rights to the asset, which treats activated phosphoinositide 3-kinase delta syndrome (APDS), an ultra-rare primary immunodeficiency disorder. The company employs approximately 250 people and generated revenues of €245 million in 2022. Pharming maintains its own manufacturing facility in Belgium for RUCONEST production, providing supply chain control for its core commercial product. The company continues advancing its pipeline focused on complement-mediated and metabolic disorders, with several programs in clinical development. Pharming is listed on Euronext Amsterdam and the Nasdaq Global Select Market under the ticker symbol "PHAR."